Daxdilimab ( DrugBank: Daxdilimab )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	1
50	皮膚筋炎／多発性筋炎	1

49. 全身性エリテマトーデス

---

臨床試験数 : 993 /  薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05430854 (ClinicalTrials.gov)	June 1, 2022	20/6/2022	Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study	An Open-Label Extension Study To Evaluate The Long- Term Safety And Tolerability Of Daxdilimab (Hzn-7734) In Subjects With Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Biological: Daxdilimab	Horizon Therapeutics Ireland DAC	NULL	Enrolling by invitation	18 Years	72 Years	All	156	Phase 2	United States;Argentina;Greece;India;Mexico;Poland;Serbia;Spain;Taiwan

50. 皮膚筋炎／多発性筋炎

---

臨床試験数 : 194 /  薬物数 : 244 - (DrugBank : 89) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05669014 (ClinicalTrials.gov)	April 2023	20/12/2022	A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)	A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Daxdilimab Subcutaneous Injection in Adult Participants With Inadequately Controlled Dermatomyositis or Anti-synthetase Inflammatory Myositis.	Idiopathic Inflammatory Myositis	Drug: Daxdilimab;Drug: Placebo	Horizon Therapeutics Ireland DAC	NULL	Not yet recruiting	18 Years	75 Years	All	96	Phase 2	NULL